The efficacy and cellular immune mechanism of NAs in the treatment of patients with chronic hepatitis B after multiple antiviral treatment failures

Trial Profile

The efficacy and cellular immune mechanism of NAs in the treatment of patients with chronic hepatitis B after multiple antiviral treatment failures

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2016

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Nov 2015 New trial record
    • 01 Oct 2015 Results published in the Hepatology Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top